Myokardia Inc (NASDAQ:MYOK) Director Kevin P. Starr sold 816,326 shares of Myokardia stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total value of $34,285,692.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Myokardia Inc (NASDAQ MYOK) traded down $0.05 during trading hours on Friday, reaching $42.00. The company had a trading volume of 286,700 shares, compared to its average volume of 745,833. Myokardia Inc has a 52 week low of $10.55 and a 52 week high of $49.55. The stock has a market cap of $1,502.91, a P/E ratio of -55.26 and a beta of 4.21.

Myokardia (NASDAQ:MYOK) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.42). Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The company had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. During the same quarter in the previous year, the business earned ($0.35) EPS. Myokardia’s revenue was up 58.6% compared to the same quarter last year. research analysts predict that Myokardia Inc will post -1.62 EPS for the current year.

Several research firms have recently commented on MYOK. Zacks Investment Research downgraded Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub upgraded Myokardia from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. JPMorgan Chase & Co. began coverage on Myokardia in a report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 price objective on the stock. ValuEngine downgraded Myokardia from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, TheStreet downgraded Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $54.83.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Myokardia by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock valued at $10,020,000 after purchasing an additional 78,800 shares during the period. JPMorgan Chase & Co. boosted its position in Myokardia by 103.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock valued at $6,243,000 after acquiring an additional 242,408 shares in the last quarter. Wells Fargo & Company MN boosted its position in Myokardia by 2,151.7% during the 3rd quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock valued at $17,887,000 after acquiring an additional 398,900 shares in the last quarter. VHCP Management II LLC bought a new stake in Myokardia during the 3rd quarter valued at approximately $11,355,000. Finally, RTW Investments LP bought a new stake in Myokardia during the 3rd quarter valued at approximately $10,882,000. Institutional investors own 63.61% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/myokardia-inc-myok-director-kevin-p-starr-sells-816326-shares.html.

Myokardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.